DOSAGE INDEX / SINGLE
Cartalax
Research, reported schedules and supply planning.
Review AED and T-31 research in renal cultures, chondrocytes and human stem cells, separating cartilage markers from proven joint repair.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 2–5 mg per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
The source acknowledges limited human dosing evidence. Cell studies do not validate this injection schedule.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 20 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- A 2014 study compared a calf-kidney polypeptide complex with T-31/AED and T-35/EDL in aging primary renal cultures. The authors associated T-31 and the complex with cell-renewal activity; the reported T-35 target was MMP-14. This distinction matters because the two synthetic sequences did not receive identical conclusions. [1]
- A 2023 experiment assessed AED and a cartilage polypeptide complex in human mesenchymal stem-cell cultures during replicative aging. The investigators reported increased expression and protein production for chondrogenic markers including SOX9, aggrecan, type II collagen and COMP. The experiment supports further investigation of cartilage differentiation, not a claim that participants regenerated cartilage. The word human describes the cell source. [2]
- A separate 2023 report examined the aging-associated secretory phenotype of chondrocytes. The authors reported that AED and the cartilage complex shifted a panel including p16, p21, p53, inflammatory cytokines and Sirt1 toward the study's reference pattern. Its endpoints were molecular measurements. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 12 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original renal-culture study
- Original stem-cell study
- Original chondrocyte study
- Neuroendocrinology Letters (2002)Further reading · Listed in reference bibliography.
- Bulletin of Experimental Biology and Medicine (2016)Further reading · Listed in reference bibliography.
- Molecular Biology Reports (2020)Further reading · Listed in reference bibliography.
- International Journal of Molecular Sciences (2023)Further reading · Listed in reference bibliography.
- Advances in Gerontology (2020)Further reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- Advances in Therapy (PubMed)Further reading · Listed in reference bibliography.
- StatPearls (NCBI Bookshelf)Further reading · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- PubChemFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.